ClinicalTrials.gg
CompletedNCT01572909EMBRACEUpdated Jun 11, 2020Results posted

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

A Phase 2 interventional study of Bendavia (MTP-131) and Placebo in Reperfusion Injury and STEMI, sponsored by Stealth BioTherapeutics Inc.. Completed at 30 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also known as MTP-131, or Bendavia) on a background of standard-of-care therapy for reduction of reperfusion injury in patients with first time acute, anterior wall ST-segment elevation myocardial infarction (STEMI).

Read the detailed description

The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide on a background of standard-of-care therapy for reduction of reperfusion injury in patients with first time acute, anterior wall STEMI.

Patients were randomized to receive either an infusion of elamipretide at 0.05 mg/kg/hr or an identically appearing placebo administered as an IV infusion at 60 mL/hr. The infusion began at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel.

The reduction of reperfusion injury, or infarct size, was estimated using the area under the curve (AUC) of the serum creatine kinase (CK) isoenzyme, as well as using magnetic resonance imaging (MRI) performed on the Day 4±1 and on Day 30±7 (both MRI assessments measured infarct size and the ratio of infarct size to myocardial mass). The analyses of cardiac MRI data were performed for both the primary endpoint population and also in all patients who had adequate Day 4/Day 30 cardiac MRI studies.

After completion of the percutaneous coronary intervention (PCI) and stenting, patients received standard medical treatment.

02

Conditions studied

  • Reperfusion Injury
  • STEMI

Keywords

  • Myocardial Reperfusion
  • Primary PCI
  • Stenting for ST-segment Elevation Myocardial Infarction
03

In context

Reperfusion Injury

260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.

This study's enrollment of 300 is above the median of 60 across 212 interventional studies indexed under Reperfusion Injury.

Browse Reperfusion Injury studies →

Lead sponsor

Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and \<85 years
  • The patient presents with first-time acute, anterior wall STEMI scheduled to undergo primary PCI and stenting.
  • The patient has symptoms of cardiac ischemia of ≥10 minutes.
  • The patient must demonstrate an anterior wall STEMI with >0.1 millivolt (mV) ST-segment elevation in at least two contiguous precordial leads (i.e., V1-V4) or presumed new left bundle branch block.
  • The time from onset of symptoms of cardiac ischemia to the anticipated time of initial PCI balloon inflation does not exceed four (4) hours and it is anticipated that the door-to-balloon time will be \<2 hours.
  • For female patients of , an adequate form of must be adhered to prior to entry into the study and for a further 3 months after the follow-up visit. Female patients of childbearing potential must have a negative serum pregnancy test prior to entry into the study.
  • Female patients not of childbearing potential (i.e. female patients who are since last regular menses, or have been surgically sterilized at least 1 year prior to screening visit) are eligible to enter the study.
  • For male patients with female partners of child-bearing potential, an adequate form of contraception must be adhered to prior to entry into the study and for a further 3 months after the post-study medical.
  • Written obtained that strictly adheres to the written guidelines from the local Institutional Review Board (IRB)/ Ethical Committee (EC).

Exclusion criteria

Exclusion Criteria

  • Cardiogenic shock or maximal systolic blood pressure (BP) \<80 mm Hg after fluid and/or vasopressor resuscitation on at least two consecutive readings.
  • Ongoing vasopressor support.
  • Uncontrolled hypertension defined as a systolic BP >180 mm Hg or a diastolic BP >110 mm Hg on at least two consecutive readings.
  • Cardiac arrest or arrhythmia requiring prolonged (>5 minutes) chest compressions/ cardiopulmonary resuscitation (CPR).
  • Prior coronary artery bypass graft surgery (CABG).
  • Prior myocardial infarction (MI).
  • Implantable cardioverter-defibrillator (ICD) or permanent pacemaker (PPM) unless known to be MRI safe. The presence of an MRI-compatible pacemaker or other MRI-compatible hardware will not be a to participation in this trial.
  • Known \<30% prior to the qualifying infarct.
  • History of hepatic disturbance or chronic renal impairment at the time of admission.
  • Cerebrovascular accident (CVA) or (TIA) within the last 30 days.
  • Any known disorder that is associated with immunologic dysfunction (e.g., cancer, lymphoma, a positive serologic test for the , or hepatitis) more recently than 6 months before presentation or the administration of drugs within 10 days of the STEMI at doses expected to be associated with immunosuppression including high dose (>2.5 mg/d hydrocortisone or equal potency of synthetic steroids), tumor necrosis factor-alpha (TNF-α) blockers or methotrexate/azathioprine.
  • Any condition that, in the Investigator's opinion, would prevent adherence to the requirements of the protocol including language barrier or current alcohol or drug abuse.
  • Contraindications (including claustrophobia) to cardiac MRI at study entry.
  • Participation in an drug or device study within the 30 days prior to enrollment into the EMBRACE-STEMI Trial or anticipated within the next 4 days.
  • Female patients who are pregnant or breastfeeding during the study or intend to within 30 days of receiving study drug.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Active comparator
    Bendavia™

    Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.

    Drug: Bendavia (MTP-131)

  • Placebo comparator
    Placebo

    Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.

    Drug: Placebo

Interventions

  • 0.05 mg/kg/hr

    Also known as: MTP-131, Elamipretide

  • DrugPlacebo

    Identically appearing placebo

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)

    Infarct size as measured by the AUC of serum CK-MB at 24 and 72 hours post-PCI

    Time frame: The initial 24 and 72 hours post-percutaneous coronary intervention (PCI)

Secondary outcomes

  1. AUC of Troponin 1 Enzyme

    Infarct size as calculated by the AUC of Troponin I Enzyme over the initial 24 and 72 hours post-PCI

    Time frame: Initial 24 and 72 hours post-PCI

  2. Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass

    Cardiac infarct size calculated as the ratio of volume of infarcted myocardium to left ventricular mass at Day 30 as measured by MRI.

    Time frame: Day 30 + 7

  3. Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI

    TIMI perfusion grade flow at completion of PCI will be categorized as 0,1, or 1.5, 2 or 2.5, 3, and treated as ordinal data, where higher score means better perfusion and lower score means worse perfusion and worse outcome.

    Time frame: Initiation to Completion of PCI, no longer than 4 hours

  4. Corrected TIMI Frame Count

    Corrected TIMI Frame Count at Completion of PCI as captured by angiogram and analyzed as a continuous variable.

    Time frame: Completion of PCI, no longer than 4 hours

  5. ST-Segmented Elevation From Pre-PCI to 24 Hours Post-PCI and Presence of ST-Segmented Resolution

    ST-Segmented Elevation from pre-PCI to 24 hours post-PCI and Presence of ST-Segmented Resolution by ECG

    Time frame: pre-PCI to 24 hours post-PCI

  6. Change in Serum Creatinine From Baseline

    Change in serum creatinine, from baseline (prior to study drug administration) to Day 30 +7 post-PCI

    Time frame: Day 30 +7

  7. Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline

    Change in eGFR from baseline (prior to study drug administration) to Day 30 +7 post-PCI

    Time frame: Day 30 +/- 7

  8. Cystatin C Change From Baseline

    Change in Cystatin C from baseline (prior to study drug administration) to Day 30 +7 post-PCI

    Time frame: Day 30 + 7

  9. Blood Urea Nitrogen (BUN) Change From Baseline

    Blood Urea Nitrogen (BUN) Change from baseline (prior to study drug administration) to Day 30 + 7 post-PCI

    Time frame: Baseline to Day 30

  10. Number and Percent of Grade 1 Episode of Contrast-Induced Nephropathy Post-PCI

    Number of Participants with Grade 1 Episode of Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data.

    Time frame: Baseline to 48 hours post PCI or MRI

  11. Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation

    Number and percent of participants with Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation Requiring Medical Intervention

    Time frame: Baseline up to 1 hour post-PCI

  12. Immediate Myocardial Complications: Mechanical Complications

    Number and Percent of Participants with Immediate Myocardial Complications: Mechanical Complications: (Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation)

    Time frame: Baseline up to 1 hour post-PCI

  13. Emergency Use of Medications During PCI Procedure

    Emergency Use of Nitroprusside, Calcium Channel Blocker, Adenosine Administration During the PCI Procedure

    Time frame: Initiation to Completion of PCI, no longer than 4 hours

  14. ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30

    NT-proBNP: Change from baseline to Day 30 +7 (Laboratory marker for chronic heart failure (CHF) and systemic inflammation.)

    Time frame: Baseline to Day 30

  15. High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30

    High Sensitivity C-Reactive Protein (hsCRP): Change from baseline to Day 30 +7 (Laboratory Marker for CHF and Systemic Inflammation)

    Time frame: Baseline to Day 30

  16. Left Ventricular (LV) Ejection Fraction (%)

    Difference in Left Ventricular (LV) Ejection Fraction (%) from Day 4 To Day 30

    Time frame: Day 4 to Day 30

  17. Difference Between Left Ventricular End Diastolic Volume, Corrected

    Difference between Left Ventricular End Diastolic Volume Corrected for Body Surface Area between Day 4 and Day 30

    Time frame: Day 4 and Day 30

  18. Difference Between Left Ventricular End Systolic Volume, Corrected

    Difference between Left Ventricular End Systolic Volume Corrected for Body Surface Area from Day 4 and Day 30

    Time frame: Day 4 and Day 30

  19. Chronic Heart Failure

    Number and Percentage of Patients with Clinical Events: Chronic Heart Failure beginning within 24 hours after PCI but within the duration of the index hospitalization (Subjects with CHF started within 24 hours after the last balloon deflation while the patient was still in the hospital {including patients who had missing discharge date}).

    Time frame: Within 24 hours after PCI

07

Results

Posted Jun 11, 2020

Participant flow

Participant flow — Overall Study
MilestoneBendavia™Placebo
Started152148
Completed120123
Not completed3225
Withdrew: Adverse event72
Withdrew: Death31
Withdrew: Lost to follow-up87
Withdrew: Physician decision11
Withdrew: Technical issues10
Withdrew: Withdrawal by subject1211
Withdrew: Infarct, comorbidity, pt refusal of exam03

Outcome measures

PrimaryArea Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)

Infarct size as measured by the AUC of serum CK-MB at 24 and 72 hours post-PCI

Time frame:
The initial 24 and 72 hours post-percutaneous coronary intervention (PCI)
Reported as:
Mean · ng*hr/mL
Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)
ng*hr/mLBendavia™Placebo
72 Hours6582.0 ± 3270.66738.3 ± 3775.4
24 Hours5252.2 ± 2667.95471.9 ± 3270.7
SecondaryAUC of Troponin 1 Enzyme

Infarct size as calculated by the AUC of Troponin I Enzyme over the initial 24 and 72 hours post-PCI

Time frame:
Initial 24 and 72 hours post-PCI
Reported as:
Mean · ng*hr/mL
AUC of Troponin 1 Enzyme
ng*hr/mLBendavia™Placebo
72 Hours5422.9 ± 3430.94647.2 ± 2834.7
24 Hours3301.4 ± 2192.92850.4 ± 1640.6
SecondaryRatio of Volume of Infarcted Myocardium to Left Ventricular Mass

Cardiac infarct size calculated as the ratio of volume of infarcted myocardium to left ventricular mass at Day 30 as measured by MRI.

Time frame:
Day 30 + 7
Reported as:
Mean · ratio
Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass
ratioBendavia™Placebo
Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass242.3 ± 87.3225.2 ± 90.70
SecondaryThrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI

TIMI perfusion grade flow at completion of PCI will be categorized as 0,1, or 1.5, 2 or 2.5, 3, and treated as ordinal data, where higher score means better perfusion and lower score means worse perfusion and worse outcome.

Time frame:
Initiation to Completion of PCI, no longer than 4 hours
Reported as:
Count of participants · Participants
Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI
ParticipantsBendavia™Placebo
Flow Grade 000
Flow Grade 1 or 1.500
Flow Grade 2 or 2.567
Flow Grade 35253
SecondaryCorrected TIMI Frame Count

Corrected TIMI Frame Count at Completion of PCI as captured by angiogram and analyzed as a continuous variable.

Time frame:
Completion of PCI, no longer than 4 hours
Reported as:
Mean · corrected frame count
Corrected TIMI Frame Count
corrected frame countBendavia™Placebo
Corrected TIMI Frame Count79.7 ± 122.8166.0 ± 286.8
SecondaryST-Segmented Elevation From Pre-PCI to 24 Hours Post-PCI and Presence of ST-Segmented Resolution

ST-Segmented Elevation from pre-PCI to 24 hours post-PCI and Presence of ST-Segmented Resolution by ECG

Time frame:
pre-PCI to 24 hours post-PCI
Reported as:
Count of participants · Participants
ST-Segmented Elevation From Pre-PCI to 24 Hours Post-PCI and Presence of ST-Segmented Resolution
ParticipantsBendavia™Placebo
Complete (>=70% resolution)3029
Partial (<70% resolution)2221
None (<30% resolution)47
SecondaryChange in Serum Creatinine From Baseline

Change in serum creatinine, from baseline (prior to study drug administration) to Day 30 +7 post-PCI

Time frame:
Day 30 +7
Reported as:
Mean · umol/L
Change in Serum Creatinine From Baseline
umol/LBendavia™Placebo
Change in Serum Creatinine From Baseline10.55 ± 17.64288.04 ± 22.462
SecondaryChange in Estimated Glomerular Filtration Rate (eGFR) From Baseline

Change in eGFR from baseline (prior to study drug administration) to Day 30 +7 post-PCI

Time frame:
Day 30 +/- 7
Reported as:
Mean · mL/min/SSA
Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline
mL/min/SSABendavia™Placebo
Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline-12.33 ± 18.873-8.94 ± 14.242
SecondaryCystatin C Change From Baseline

Change in Cystatin C from baseline (prior to study drug administration) to Day 30 +7 post-PCI

Time frame:
Day 30 + 7
Reported as:
Mean · mg/L
Cystatin C Change From Baseline
mg/LBendavia™Placebo
Cystatin C Change From Baseline0.19 ± 0.3410.19 ± 0.226
SecondaryBlood Urea Nitrogen (BUN) Change From Baseline

Blood Urea Nitrogen (BUN) Change from baseline (prior to study drug administration) to Day 30 + 7 post-PCI

Time frame:
Baseline to Day 30
Reported as:
Mean · mmol/L
Blood Urea Nitrogen (BUN) Change From Baseline
mmol/LBendavia™Placebo
Blood Urea Nitrogen (BUN) Change From Baseline-0.13 ± 1.6030.13 ± 2.207
SecondaryNumber and Percent of Grade 1 Episode of Contrast-Induced Nephropathy Post-PCI

Number of Participants with Grade 1 Episode of Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data.

Time frame:
Baseline to 48 hours post PCI or MRI
Reported as:
Count of participants · Participants
Number and Percent of Grade 1 Episode of Contrast-Induced Nephropathy Post-PCI
ParticipantsBendavia™Placebo
Yes1711
No4149
SecondaryImmediate Myocardial Complications: Ventricular Tachycardia or Fibrillation

Number and percent of participants with Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation Requiring Medical Intervention

Time frame:
Baseline up to 1 hour post-PCI
Reported as:
Count of participants · Participants
Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation
ParticipantsBendavia™Placebo
Yes23
No5657
SecondaryImmediate Myocardial Complications: Mechanical Complications

Number and Percent of Participants with Immediate Myocardial Complications: Mechanical Complications: (Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation)

Time frame:
Baseline up to 1 hour post-PCI
Reported as:
Count of participants · Participants
Immediate Myocardial Complications: Mechanical Complications
ParticipantsBendavia™Placebo
Immediate Myocardial Complications: Mechanical Complications10
SecondaryEmergency Use of Medications During PCI Procedure

Emergency Use of Nitroprusside, Calcium Channel Blocker, Adenosine Administration During the PCI Procedure

Time frame:
Initiation to Completion of PCI, no longer than 4 hours
Reported as:
Count of participants · Participants
Emergency Use of Medications During PCI Procedure
ParticipantsBendavia™Placebo
Yes53
No5357
SecondaryProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30

NT-proBNP: Change from baseline to Day 30 +7 (Laboratory marker for chronic heart failure (CHF) and systemic inflammation.)

Time frame:
Baseline to Day 30
Reported as:
Mean · pg/mL
ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30
pg/mLBendavia™Placebo
ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 301828.45 ± 3427.4081582.67 ± 1502.985
SecondaryHigh Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30

High Sensitivity C-Reactive Protein (hsCRP): Change from baseline to Day 30 +7 (Laboratory Marker for CHF and Systemic Inflammation)

Time frame:
Baseline to Day 30
Reported as:
Mean · mg/L
High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30
mg/LBendavia™Placebo
High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30-1.03 ± 7.072-0.91 ± 7.024
SecondaryLeft Ventricular (LV) Ejection Fraction (%)

Difference in Left Ventricular (LV) Ejection Fraction (%) from Day 4 To Day 30

Time frame:
Day 4 to Day 30
Reported as:
Mean · percentage of blood volume
Left Ventricular (LV) Ejection Fraction (%)
percentage of blood volumeBendavia™Placebo
Left Ventricular (LV) Ejection Fraction (%)2.1 ± 6.42.5 ± 8.3
SecondaryDifference Between Left Ventricular End Diastolic Volume, Corrected

Difference between Left Ventricular End Diastolic Volume Corrected for Body Surface Area between Day 4 and Day 30

Time frame:
Day 4 and Day 30
Reported as:
Mean · mL/m2
Difference Between Left Ventricular End Diastolic Volume, Corrected
mL/m2Bendavia™Placebo
Difference Between Left Ventricular End Diastolic Volume, Corrected8.6 ± 12.66.2 ± 15.1
SecondaryDifference Between Left Ventricular End Systolic Volume, Corrected

Difference between Left Ventricular End Systolic Volume Corrected for Body Surface Area from Day 4 and Day 30

Time frame:
Day 4 and Day 30
Reported as:
Mean · mL/m²
Difference Between Left Ventricular End Systolic Volume, Corrected
mL/m²Bendavia™Placebo
Difference Between Left Ventricular End Systolic Volume, Corrected2.7 ± 8.01.5 ± 12.5
SecondaryChronic Heart Failure

Number and Percentage of Patients with Clinical Events: Chronic Heart Failure beginning within 24 hours after PCI but within the duration of the index hospitalization (Subjects with CHF started within 24 hours after the last balloon deflation while the patient was still in the hospital {including patients who had missing discharge date}).

Time frame:
Within 24 hours after PCI
Reported as:
Count of participants · Participants
Chronic Heart Failure
ParticipantsBendavia™Placebo
Yes815
No5045

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bendavia™10/150 (6.7%)20/150 (13.3%)112/150 (74.7%)
Placebo3/147 (2%)14/147 (9.5%)106/147 (72.1%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventBendavia™Placebo
Cardiogenic ShockCardiac disorders4/1500/147
Acute Myocardial InfarctionCardiac disorders1/1502/147
PneumoniaInfections and infestations2/1502/147
Cardiac FailureCardiac disorders0/1502/147
Thrombosis in DeviceGeneral disorders2/1500/147
Ventricular FibrillationCardiac disorders1/1501/147
Cardiac tamponadeCardiac disorders0/1501/147
Cardiac ArrestCardiac disorders0/1501/147
Gastrointestinal HaemorrhageGastrointestinal disorders0/1501/147
Pancreatic NeoplasmsNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1501/147
Most frequent other events
Showing 10 of 46
Most frequent other events
EventBendavia™Placebo
HypercholesterolaemiaMetabolism and nutrition disorders30/15019/147
Cardiac FailureCardiac disorders28/15029/147
HypokalaemiaMetabolism and nutrition disorders27/15027/147
AnxietyPsychiatric disorders9/15014/147
Diabetes mellitusMetabolism and nutrition disorders12/1507/147
Angina PectorisCardiac disorders11/1506/147
HypertensionVascular disorders11/1509/147
Intracardiac ThrombusCardiac disorders9/15010/147
PyrexiaGeneral disorders5/1509/147
HyperlipidaemiaMetabolism and nutrition disorders6/1509/147

Baseline characteristics

300 patients were randomized and only 297 were included in the Safety Population, which consists of all patients who took any fraction of study drug using actual treatment received. If patient was randomized to placebo and received elamipretide, patient's actual treatment was recognized as elamipretide (and vice versa).

Age, Continuous
Age, Continuous(years)Bendavia™PlaceboTotal
Mean60.7 ± 1160.1 ± 10.660.4 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Bendavia™PlaceboTotal
Female452873
Male105119224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bendavia™PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander011
Black or African American000
White150146296
More than one race000
Unknown or Not Reported000
08

Study locations

30 sites
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Creighton Cardiac Center
    Omaha, Nebraska 68131, United States
  • Universitätsmedizin Berlin, Charité Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Staedtische Kliniken Bielefeld
    Bielefeld, 33604, Germany
  • Marienhaus Klinikum Eifel
    Bitburg, 54634, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, 79095, Germany
  • Klinikum Herford
    Herford, 32049, Germany
  • Robert-Bosch-Krankenhaus Kardiologie
    Stuttgart, 70376, Germany
  • Helios Klinikum Wuppertal, Herzzentrum Elberfeld
    Wuppertal, 42117, Germany
  • Gottsegen Gyorgy Orszagos Kardiologiai Intezet
    Budapest, 1096, Hungary
  • Semmelweis Egyetem Kardiológiai Központ, Városmajor u. 68
    Budapest, 1122, Hungary
  • Honvédkórház-Állami Egészségügyi Központ
    Budapest, 1134, Hungary
  • PTE Klinikai Központ Szívgyógyászati Klinika
    Pecs, H-7624, Hungary
  • Szent György Kórház, II. Belgyógyászati Osztály
    Szekesfehervar, H-8000, Hungary
  • Zala Megyei Kórház, Kardiológiai Osztály, Zrínyi Miklós út 1.
    Zalaegerszeg, H-8900, Hungary
  • Medical University of Bialystok
    Bialystok, 15-276, Poland
  • SPSK Nr 7 Klaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszka Gieca, III Oddzial Kardiologii, Zklad Kardiologii Inwazjnejul, Ziolowa 45-47
    Katowice, 40-635, Poland
  • SPSK Nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszaka Gieca, I Oddzial Kardiologii, ul. Ziolowa 45-47
    Katowice, 40-635, Poland
  • Wojewodzki Szpital Zespolony w Kielcach, Swietokrzyskie Centrum Kardiologii
    Kielce, 25-736, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pwla II, Centrum Interwencyjnego Leczenia Chorob Serca i Naczyn z Pododdzialem Kariologii Interwencyjnej
    Kraków, 31-202, Poland
  • Wojewodzki Specjalistyczny Szpital im WI. Bieganskiego, II Katedra i Klinika Kardiologii Uniwersytetu Medycznego w Lodzi, Pracownia Kardiologii Inwazyinej, ul. Kniaziewicza 1/5
    Lodz, 91-347, Poland
  • SP ZOZ Wojewodzkie Centrum Medyczne, Zaklad Diagnostyki Obrazowej, AI. W. Witosa 26
    Opole, 45-418, Poland
  • Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii
    Oswiecim, 32-600, Poland
  • Szpital Bielanski im. ks. Jerzego Popieluszki
    Warsaw, 01-809, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Pracownia Kardiologii Inwazyjnej
    Warsaw, 02-097, Poland
  • Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego
    Warsaw, 04-628, Poland
  • Dolnoslaski Szpital Specjalistyczny im. T. Marciniaka, Centrum Medycyny Ratunkowe
    Wroclaw, 50-420, Poland
  • Wojewodzki Szpital Specjalistyczny we Wroclawiu, Oddzial Kardiologiczny, ul. H. Kamieskiego 73a
    Wroclaw, 51-124, Poland
  • Samodzielny Publiczny Szpital Wojewodzki im. Papieza Jana Pawla II w Zamosciu, Oddzial Kardiologii z Pododdzialem Intensywnej Terapil Kardiologicznej, ul. Aleje Jana Pawta II 10
    Zamosc, 22-400, Poland
09

References and documents

Publications

  • Daaboul Y, Korjian S, Weaver WD, Kloner RA, Giugliano RP, Carr J, Neal BJ, Chi G, Cochet M, Goodell L, Michalak N, Rusowicz-Orazem L, Alkathery T, Allaham H, Routray S, Szlosek D, Jain P, Gibson CM. Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). Am J Cardiol. 2016 Sep 1;118(5):625-31. doi: 10.1016/j.amjcard.2016.06.025. Epub 2016 Jun 15. PubMed 27392509 ↗
  • Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, Gibson CM. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013 Apr;165(4):509-514.e7. doi: 10.1016/j.ahj.2012.12.008. Epub 2013 Feb 15. PubMed 23537966 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Nov 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2020, 5 years 7 months after primary completion. A results delay was requested in Nov 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2012
First posted
Apr 6, 2012
Start
Apr 2012
Primary completionActual
Nov 2014
CompletionActual
Feb 2015
Results delay requested
Nov 11, 2015
Results first posted
Jun 11, 2020
Last update
Jun 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01572909
Collaborators
ICON Clinical Research
Responsible party
Sponsor
First posted
Apr 6, 2012
Start date
Apr 2012
Primary completion
Nov 2014
Completion
Feb 2015
Results posted
Jun 11, 2020
Last update
Jun 11, 2020

Study contacts

Anjan Chakrabarti, MD
principal investigator · Beth Israel Deaconess Medical Center, Interventional Cardiology, 185 Pilgrim Rd, Baker 4, Boston, MA 02215
C. M. Gibson, MD
study chair · Beth Israel Deaconess Medical Center, Interventional Cardiology, 185 Pilgrim Rd, Baer 4, Boston, MA 02215

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion